| GNRIhigh (n = 147) | GNRIlow (n = 201) | Pvalue |
---|---|---|---|
Age (median) | 81 (75–95) | 83 (75–98) |  < 0.001 |
Sex | |||
 Male | 69 (46.9%) | 92 (45.8%) | 0.913 |
 Female | 78 (53.1%) | 109 (54.2%) |  |
ECOG PS | |||
 0, 1 | 121 (82.3%) | 113 (56.2%) |  < 0.001 |
 2, 3, 4 | 26 (17.7%) | 88 (43.8%) |  |
BMI | 23.1 (17.8–28.7) | 19.5 (11.7–28.1) |  < 0.001 |
ALB | 3.9 (2.8–4.9) | 3.1 (1.5–4.8) |  < 0.001 |
CRP | 0.16 (0.02–10.30) | 0.69 (0.02–34.70) |  < 0.001 |
Preoperative CEA | 3.6 (0.8–366.0) | 4.9 (1.0–886.3) | 0.015 |
Preoperative CA19-9 | 11.0 (0–8882.2) | 9.1 (0–5782.0) | 0.457 |
Location | |||
 Colon | 116 (78.9%) | 160 (79.6%) | 0.894 |
 Rectum | 31 (21.1%) | 41 (20.4%) |  |
Obstruction | |||
 Absent | 127 (86.4%) | 135 (67.2%) |  < 0.001 |
 Present | 20 (13.6%) | 66 (32.8%) |  |
Perforation | |||
 Absent | 143 (97.3%) | 192 (95.5%) | 0.569 |
 Present | 4 (2.7%) | 9 (4.5%) |  |
Histology a | |||
 tub | 135 (91.8%) | 176 (87.6%) | 0.222 |
 por, muc | 12 (8.2%) | 25 (12.4%) |  |
Pathologic T stage b | |||
 T1, T2, T3 | 133 (90.5%) | 152 (75.6%) |  < 0.001 |
 T4 | 14 (9.5%) | 49 (24.4%) |  |
Lymphatic invasion c | |||
 Ly0, 1a | 129 (87.8%) | 154 (76.6%) | 0.008 |
 Ly1b, c | 18 (12.2%) | 47 (23.4%) |  |
Vascular invasion d | |||
 V0, 1a | 110 (74.8%) | 154 (76.6%) | 0.706 |
 V1b, c | 37 (25.2%) | 47 (23.4%) |  |
Adjuvant chemotherapy | |||
 Absent | 128 (87.1%) | 179 (89.1%) | 0.615 |
 Present | 19 (12.9%) | 22 (10.9%) |  |